	US 11,697,674 B2
	Human chorionic gonadotropin variant peptides and treatment of breast cancer
Jose Russo, Philadelphia, PA (US); Yanrong Su, Philadelphia, PA (US); Julia Santucci Pereira Del Buono, Philadelphia, PA (US); and Mark Andrake, Philadelphia, PA (US)
Assigned to Institute For Cancer Research, Philadelphia, PA (US)
Appl. No. 16/756,191
Filed by Institute For Cancer Research, Philadelphia, PA (US)
PCT Filed Oct. 15, 2018, PCT No. PCT/US2018/055841 § 371(c)(1), (2) Date Apr. 15, 2020, PCT Pub. No. WO2019/079167, PCT Pub. Date Apr. 25, 2019.
Claims priority of provisional application 62/572,615, filed on Oct. 16, 2017.
Prior Publication US 2021/0188935 A1, Jun. 24, 2021 Prior Publication US 2022/0041679 A9, Feb. 10, 2022
Int. Cl. C07K 14/59 (2006.01); A61K 47/69 (2017.01); A61K 31/138 (2006.01); A61K 38/24 (2006.01); A61K 31/706 (2006.01)

CPC C07K 14/59 (2013.01) [A61K 31/138 (2013.01); A61K 31/706 (2013.01); A61K 38/24 (2013.01); A61K 47/6929 (2017.08)]

10 Claims

1. A method for treating a subject having breast cancer comprising administering to the subject in need thereof at least one peptide comprising at least 90% identity to the amino acid sequence Xaa-Xaa-Cys-Xaa-Arg-Ser-Xaa-Thr-Asp-Cys-Gly-Gly-Pro-Lys-Asp-His-Gly-Ser-Xaa-Arg-Ser-Ly s-Lys-Thr-Met-Xaa-Xaa-Gln-Lys-Asn-Xaa-Xaa-Ser-Glu (SEQ ID NO:3).